Health Care·Pharmaceuticals·$277.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.01 | N/A | -12.55% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.01 | N/A | -12.55% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management conveyed a cautious outlook, highlighting ongoing challenges in the market. They reiterated their commitment to long-term growth strategies.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term strategies despite short-term setbacks.
This earnings report indicates that Novartis faced challenges in the fourth quarter, resulting in an EPS miss. The lack of revenue data and guidance may leave investors uncertain about the company's future performance. The stock reaction is not available, but the overall tone from management suggests a cautious approach moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ERICSSON B ADR
Jan 25, 2010